Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Warner-Lambert Company

Merrell Dow Pharmacueticals Inc.

Aventis Pharma Limited

Niall S Doherty

George Ku

Boyd Lynn Harrison

Jeffrey Paul Whitten

Ian A McDonald

Laurie E Lambert

Norton P Peet

James R McCarthy

Philippe Bey

Michael R Angelastro

Shujaath Mehdi

Michael John Janusz

Esa T Jarvi

Dennis Allen Smith

Jeffrey A Wolos

Ian A Mcdonald

The present invention is directed to methods of stimulating hair growth by administering particular benzopyran compounds.

Method of stimulating hair growth using benzopyrans

The present invention is directed to a new class of compound which are useful as inhibitors of the biosynthesis of nitric oxide.

Inhibitors of nitric oxide biosynthesis

Novel compounds which are chemically linked inhibitors of the proteases Elastase and Cathepsin G prevent connective tissue degradation associated with neutrophil induced inflammatory disease.

Inhibitors of Cathepsin G and elastase for preventing connective tissue

The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-vinylhalo-aristeromycin/adenosine analogs.

5'-vinylhalo-aristeromycin/adenosine analogs and immunosuppressants

The present invention is a method of treating hypotension and shock using select ornithine or N.sup.G -arginine derivatives.

Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-di-isobutyl-6-(N,N-dimethylaminomethyl)-phenol.

Method of inhibiting interleukin-1 release

Methods useful for inhibiting the release of interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1-mediated inflammation, comprising administration of an effective amount of a pharmaceutically acceptable antioxidant compound such as disulfiram, tetrakis [3-(2,6-di-tert-butyl-4-hydroxyphenyl)propionyloxy methyl]methane or 2,4-disobutyl-6-(N,N-dimethylaminomethyl)-phenol.

Methods useful for inhibiting the release of Interleukin-1 and for alleviating interleukin-1 mediated conditions, such as IL-1 mediated inflammation, comprising administration of an effective amount of an alkylidenedithiobis(substituted)phenol, preferably, 4,4'-(isopropylidenedithio(bis(2,6-di-tert-butyl) phenol, generically known as probucol.

Method of inhibiting interleukin-1 release and alleviating interleukin-1

N-(1,3-dithiolan-2-ylidene)-4-alkylanilines are useful as anti-inflammatory agents, as analgesic agents and as antiasthmatic agents. The compounds involved can be prepared by the reaction of an appropriate 4-alkylaniline with a methyl(1,3-dithiolan-2-ylidene)sulfonium salt or with carbon disulfide and ethylene dibromide in the presence of a base.

Anti-inflammatory agents and antiasthmatic agents

N-(1,3-dithiolan-2-ylidene)-4-alkylanilines having a hydroxy, alkoxy or alkanoyloxy substituent on the alkyl group are useful as anti-inflammatory agents, as analgesic agents and as antiasthmatic agents. The compounds involved can be prepared by the reaction of an appropriate 4-alkylaniline with a methyl(1,3-dithiolan-2-ylidene)sulfonium salt or with carbon disulfide and ethylene dibromide in the presence of a base.

Growing community of inventors

Lyme, CT, United States of America

Niall S Doherty